The study confirmed that immunotherapy combined with chemotherapy can prolong the life span of triple negative breast cancer patients

Triple negative breast cancer usually affects young women, many of whom are diagnosed in their 40s or 50s The standard treatment for this cancer is chemotherapy, but most patients will soon develop resistance If the disease spreads to other parts of the body, the life span is usually only 12 to 15 months In a new study, researchers from Queen Mary's College at the University of London and St Bartholomew's Hospital in the UK conducted a clinical trial of immunotherapy (http://www.chemdrug.com/sell/24/) The combination of immunotherapy and chemotherapy can adjust the immune system of patients with triple negative breast cancer, which can attack the cancer and prolong the life of patients for up to 10 months The results were published online on October 20, 2018 in the Journal of New England Journal of medicine and at the 2018 European Society of oncology in Munich, Germany The clinical study also showed that the combination treatment reduced the risk of death or cancer progression by as much as 40% The new treatment combines the standard weekly chemotherapy drug (http://www.chemdrug.com/) albumin with paclitaxel and the biweekly immunotherapy drug atezolizumab (trade name tecentriq) The mechanism of this combination therapy is that albumin combined with paclitaxel "roughens up" the cancer surface, which enables the immune system to better recognize the cancer as an alien and fight against it Based on the results of this clinical trial, the new treatment is currently being reviewed by the UK health authorities, and these researchers hope that in the near future this treatment can be used in the NHS During this period, three negative breast cancer patients at Saint Bartholomew hospital received immunotherapy in ongoing clinical trials.